Fitzpatrick Cella

1. Sanofi, Dabur Patent Dispute Over Eloxatin Survives

Friday, Mar 19, 2010

A federal judge has denied opposing summary judgment motions for plaintiff Sanofi-Aventis US LLC and defendants Fresenius Kabi Oncology PLC and Dabur Pharma Ltd. in an infringement suit over two patents related to the popular colon cancer drug Eloxatin.

2. Fresenius Infringes Sanofi's Eloxatin Patent: Judge

Monday, Mar 15, 2010

Sanofi-Aventis US LLC has won summary judgment of infringement against Fresenius Kabi Pharma Ltd., scoring a victory in its bid to keep generic versions of popular colon cancer drug Eloxatin off the market.

3. Sanofi Loses Injunction Bid In Generic Eloxatin Spat

Wednesday, Mar 10, 2010

A federal judge has again denied Sanofi-Aventis US LLC's request for a preliminary injunction against Fresenius Kabi Pharma Ltd., one of the last remaining defendants in the pharmaceutical giant's battle to keep generic versions of popular colon cancer drug Eloxatin off the market.

4. Celgene, Novartis Resolve ADHD Patent Suits

Monday, Mar 08, 2010

Celgene Corp. and Novartis AG have reached an agreement to settle separate patent infringement suits against KV Pharmaceutical Co. and IntelliPharmaCeutics Corp. over drugs that treat attention deficit hyperactivity disorder, the latter of which brought antitrust counterclaims against the pharmaceutical companies.

5. Sanofi Loses Last-Ditch Bid To Upend Eloxatin Deal

Tuesday, Mar 02, 2010

A federal judge has deemed enforceable a deal that Sanofi-Aventis U.S. LLC reached with Sun Pharmaceutical Industries Ltd. ending a patent fight over generic versions of Sanofi's colon cancer drug Eloxatin, rejecting Sanofi's second attempt to undo the deal.

6. Teva, Novartis Settle Suit Over Generic Famvir

Tuesday, Feb 16, 2010

Israel-based Teva Pharmaceutical Industries Ltd.'s U.S. unit has settled a patent infringement suit brought by Novartis AG over a generic version of genital herpes drug Famvir.

7. Perrigo ANDA Doesn't Infringe Mucinex Patent: Judge

Friday, Feb 12, 2010

A federal judge has handed Perrigo Co. victory in a suit brought by a Reckitt Benckiser Group PLC subsidiary, ruling that the generic-drug manufacturer did not infringe a patent for the expectorant Mucinex through its attempt to introduce its own version of the drug.

8. Celgene, Novartis Settle With Teva In Focalin IP Suits

Tuesday, Feb 02, 2010

Celgene Corp. and Novartis Pharmaceuticals Corp. have settled a series of lawsuits against Teva Pharmaceuticals USA Inc. over its plan to market a generic version of attention deficit hyperactivity disorder treatment Focalin XR.

9. Law Firms Open Their Wallets For Haiti

Friday, Jan 15, 2010

As the world scrambles to come to Haiti's aid in the wake of Tuesday's devastating earthquake, law firms are stepping up in both traditional and novel ways. Over 80 firms responded to a Law360 query into what they are doing financially and otherwise to respond to the Haitian crisis.

10. Genzyme, Daiichi Try To Halt Impax’s Generic Welchol

Friday, Jan 15, 2010

Genzyme Corp. and Daiichi Sankyo Inc. have dragged Impax Laboratories to court in an effort to block it from marketing a generic version of their cholesterol drug Welchol.

11. Kirkland & Ellis Patent Pro Joins Quinn Emanuel

Thursday, Jan 14, 2010

Patent litigator Peter Armenio has joined the New York office of international law firm Quinn Emanuel Urquhart Oliver & Hedges LLP from rival Kirkland & Ellis LLP.

12. Apotex Seeks Stay In Plavix Suit Pending USPTO Ruling

Monday, Jan 11, 2010

Apotex Inc. is asking a federal court to stay its long-running patent suit with Sanofi-Aventis SA over the blood-thinning drug Plavix while the U.S. Patent and Trademark Office re-examines Sanofi's patent for the drug.

13. Novartis, Roxane Drop Most Famvir Patent Claims

Wednesday, Jan 06, 2010

A federal judge has approved a joint move by Novartis Pharmaceuticals Corp. and Roxane Laboratories Inc. to dismiss claims regarding three of four patents in the drugmakers' battle over Novartis herpes treatment Famvir.

14. EIG, Fitch Settle Newsletter Copyright Case

Monday, Dec 14, 2009

Fitch Inc. has settled a lawsuit alleging that the ratings agency violated copyright law by electronically forwarding Energy Intelligence Group Inc.'s subscription newsletters.

15. Law360 Ranks Largest IP Practices

Friday, Dec 04, 2009

Finnegan Henderson LLP, Fish & Richardson and Morrison & Foerster LLP topped the Law360 IP 100 this year, boasting the largest intellectual property practices in the United States, as measured by the number of practicing lawyers.

16. CORRECTED: Warner Chilcott Birth Control IP Suit To Be Heard In Del.

Monday, Nov 02, 2009

Warner Chilcott PLC's allegations that Lupin Ltd. has infringed patents for its birth control drugs Loestrin 24 Fe and Femcon Fe will move forward in the U.S. District Court for the District of Delaware, now that the company has dropped identical protective suits in another court.

17. Teva Hits Back In Gilead Patent Suit Over HIV Drug

Monday, Oct 12, 2009

Teva Pharmaceutical Industries Ltd. has struck back with patent invalidity counterclaims against rival Gilead Sciences Inc. in an infringement case involving drug treatments for HIV.

18. Impax Agrees to Settle Flomax Patent Dispute

Wednesday, Oct 07, 2009

Impax Laboratories Inc. has reached an agreement with drugmakers Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals Inc. to settle a patent dispute related to a generic version of Flomax, a drug used to treat the symptoms of an enlarged prostate.

19. Sanofi-Sun Settlement In Eloxatin Suit Ruled Valid

Tuesday, Oct 06, 2009

A judge has ruled that Sanofi-Aventis is bound to a settlement agreement it reached with Sun Pharmaceutical Industries Ltd. in a patent infringement suit over generic versions of Sanofi’s popular colon cancer drug Eloxatin, even though it failed to sign the agreement.

20. Genzyme Sues Endo In Latest Renagel ANDA Suit

Tuesday, Oct 06, 2009

Genzyme Corp. has accused Endo Pharmaceuticals Inc. of infringing a patent for Renagel by seeking regulatory permission to sell a generic version of the kidney disease treatment in the U.S. before the patent expires.